Onychomycosis: Current Trends in Diagnosis and Treatment

被引:1
作者
Westerberg, Dyanne P. [1 ,2 ]
Voyack, Michael J. [2 ,3 ]
机构
[1] Rowan Univ, Cooper Med Sch, Chair Family & Community Med, Camden, NJ USA
[2] Cooper Univ Hosp, Camden, NJ 08103 USA
[3] Rowan Univ, Cooper Med Sch, Glassboro, NJ USA
关键词
SYSTEMIC ANTIFUNGAL AGENTS; 930-NM LIGHT EXPOSURE; TOENAIL ONYCHOMYCOSIS; ORAL TERBINAFINE; TRIAL; NAIL; EPIDEMIOLOGY; EFFICACY; MODERATE; MILD;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Onychomycosis is a fungal infection of the nails that causes discoloration, thickening, and separation from the nail bed. Onychomycosis occurs in 10% of the general population, 20% of persons older than 60 years, and 50% of those older than 70 years. It is caused by a variety of organisms, but most cases are caused by dermatophytes. Accurate diagnosis involves physical and microscopic examination and culture. Histologic evaluation using periodic acid Schiff staining increases sensitivity for detecting infection. Treatment is aimed at eradication of the causative organism and return to a normal appearance of the nail. Systemic antifungals are the most effective treatment, with meta-analyses showing mycotic cure rates of 76% for terbinafine, 63% for itraconazole with pulse dosing, 59% for itraconazole with continuous dosing, and 48% for fluconazole. Concomitant nail debridement further increases cure rates. Topical therapy with ciclopirox is less effective; it has a failure rate exceeding 60%. Several nonprescription treatments have also been evaluated. Laser and photodynamic therapies show promise based on in-vitro evaluation, but more clinical studies are needed. Despite treatment, the recurrence rate of onychomycosis is 10% to 50% as a result of reinfection or lack of mycotic cure. Copyright (C) 2013 American Academy of Family Physicians.
引用
收藏
页码:762 / 770
页数:9
相关论文
共 43 条
  • [1] Alberhasky Robert C, 2004, Clin Podiatr Med Surg, V21, P565, DOI 10.1016/j.cpm.2004.06.001
  • [2] Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis
    Avner, S
    Nir, N
    Henri, T
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2005, 16 (5-6) : 327 - 330
  • [3] PAS is optimal for diagnosing onychomycosis
    Barak, Orr
    Asarch, Adam
    Horn, Thomas
    [J]. JOURNAL OF CUTANEOUS PATHOLOGY, 2010, 37 (10) : 1038 - 1040
  • [4] Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy
    Baran, R
    Kaoukhov, A
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2005, 19 (01) : 21 - 29
  • [5] Bennet JE., 2011, Goodman and Gilman?s The pharmacological basis of therapeutics, V12th, P1571
  • [6] Prediction of diabetic foot ulcer occurrence using commonly available clinical information - The Seattle diabetic foot study
    Boyko, EJ
    Ahroni, JH
    Cohen, V
    Nelson, KM
    Heagerty, PJ
    [J]. DIABETES CARE, 2006, 29 (06) : 1202 - 1207
  • [7] BUCK DS, 1994, J FAM PRACTICE, V38, P601
  • [8] The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: A meta-analysis
    Chang, Chia-Hsuin
    Young-Xu, Yinong
    Kurth, Tobias
    Orav, John E.
    Chan, Arnold K.
    [J]. AMERICAN JOURNAL OF MEDICINE, 2007, 120 (09) : 791 - U3
  • [9] Topical treatments for fungal infections of the skin and nails of the foot (Withdrawn Paper. 2007, art. no. CD001434)
    Crawford, F.
    Hollis, S.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (03):
  • [10] Novel Treatment of Onychomycosis using Over-the-Counter Mentholated Ointment: A Clinical Case Series
    Derby, Richard
    Rohal, Patrick
    Jackson, Constance
    Beutler, Anthony
    Olsen, Cara
    [J]. JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE, 2011, 24 (01) : 69 - 74